Detection of Common Disease-Causing Mutations in Mitochondrial DNA (Mitochondrial Encephalomyopathy, Lactic Acidosis with Stroke-Like Episodes MTTL1 3243 A>G and Myoclonic Epilepsy Associated with Ragged-Red Fibers MTTK 8344A>G) by Real-Time Polymerase Chain Reaction by Fan, Hongxin et al.
Detection of Common Disease-Causing
Mutations in Mitochondrial DNA (Mitochondrial
Encephalomyopathy, Lactic Acidosis with Stroke-
Like Episodes MTTL1 3243 AG and Myoclonic
Epilepsy Associated with Ragged-Red Fibers MTTK
8344AG) by Real-Time Polymerase Chain Reaction
Hongxin Fan,* Chris Civalier,* Jessica K. Booker,*
Margaret L. Gulley,*† Thomas W. Prior,‡ and
Rosann A. Farber*†§
From the Department of Pathology and Laboratory Medicine,*
Lineberger Comprehensive Cancer Center,† and the Department
of Genetics,§ The University of North Carolina, Chapel Hill, North
Carolina; and the Department of Pathology,‡ Ohio State
University, Columbus, Ohio
The 3243A>G mutation in the MTTL1 (tRNALeu) gene
and the 8344A>G mutation in the MTTK (tRNALys)
gene are the most common mutations found in mito-
chondrial encephalomyopathy, lactic acidosis with
stroke-like episodes and myoclonic epilepsy associ-
ated with ragged-red fibers, respectively. These mito-
chondrial DNA mutations are usually detected by con-
ventional polymerase chain reaction followed by
restriction enzyme digestion and gel electrophoresis.
We developed a LightCycler real-time polymerase
chain reaction assay to detect these two mutations
based on fluorescence resonance energy transfer
technology and melting curve analysis. Primers and
fluorescence-labeled hybridization probes were de-
signed so that the sensor probe spans the mutation
site. The observed melting temperatures differed in
the mutant and wild-type DNA by 9°C for the MTTL1
gene and 6°C for the MTTK gene. This method cor-
rectly identified all 10 samples that were 3243A>G
mutation-positive, all 4 samples that were 8344A>G
mutation-positive, and all 30 samples that were neg-
ative for both mutations, as previously identified by
traditional gel-based methods. This LightCycler assay
is a rapid and reliable technique for molecular diag-
nosis of these mitochondrial gene mutations. (J Mol
Diagn 2006, 8:277–281; DOI: 10.2353/jmoldx.2006.050066)
Mitochondrial encephalomyopathy, lactic acidosis with
stroke-like episodes (MELAS) and myoclonic epilepsy
associated with ragged-red fibers (MERRF) are diseases
caused by mutations in mitochondrial DNA (mtDNA). The
3243AG mutation in the MTTL1 (tRNALeu) gene and
the 8344AG mutation in the MTTK (tRNALys) gene of
mtDNA account for about 80% of MELAS and MERRF
cases, respectively.1,2 In clinical laboratories, these
mtDNA mutations have often been detected using poly-
merase chain reaction (PCR) followed by restriction frag-
ment length polymorphism (RFLP) analysis by gel elec-
trophoresis. Although this method is effective, it is
relatively time consuming and introduces the risk of cross
contamination by PCR products.
Detection of mutations in mtDNA can be accomplished
by performing continuous PCR amplification and melting
curve analysis using fluorescent hybridization probes on
a LightCycler. Two fluorescently labeled, sequence-spe-
cific probes, one of which spans the mutation site, are
used for each of these assays. When the mutation-span-
ning sensor probe and an anchor probe are annealed in
tandem to the target mtDNA, fluorescence resonance
energy transfer results in increased fluorescent energy
that is detectable by the LightCycler. After amplification
by PCR, melting curve analysis of the product is accom-
plished by heating to dissociate the sensor probe from its
target, which leads to a decrease in fluorescence. The
temperature at which the probe dissociates depends on
whether a mismatch is present, with a mismatch yielding
a lower melting temperature (Tm).
3,4
We have developed novel PCR assays to detect the
two common mtDNA mutations (3243AG and
8344AG) in MELAS and MERRF using fluorescence
resonance energy transfer technology and melting curve
analysis on a real-time PCR platform.5,6 The assays were
analytically validated by optimization of amplification
conditions and evaluation of performance characteristics
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on known positive and negative samples, as defined by
conventional PCR and RFLP methods.
Materials and Methods
Sample Preparation
Thirteen cases of clinically confirmed MELAS (n  10) or
MERRF (n  3) and 30 unaffected controls were identi-
fied from the records of the University of North Carolina
Hospital and the Ohio State University Molecular Labora-
tories. Genotypes were determined by traditional PCR
and RFLP methods.7,8 DNA from the NA11906 lympho-
blastoid cell line, derived from a patient known to carry
the MERRF MTTK 8344AG mutation (Coriell Institute,
Camden, NJ), was also included. The study was per-
formed in compliance with local and federal regulations
and under the supervision of our Institutional Review
Board.
mtDNA was extracted from blood using the MagNA
Pure LC with DNA Isolation kit I reagents, according to
the manufacturer’s protocol (Roche Diagnostics, India-
napolis, IN) or by manual methods.9
Primers, Probes, and Amplification
Primer and probe sets were designed based on the
Human Mitochondrial DNA Cambridge Reference Se-
quence (GenBank no. NC_001807) and guidelines set
forth by Roche Diagnostics,4 with the assistance of “The
LightCycler Probe Design Software” (version 1.0; Roche
Diagnostics). Primers and probes were synthesized by
TIB Molbiol (Berlin, Germany). Several sets of primers
and probes were tested for their ability to detect the
mutations, including two pairs of primers and three sets
of probes for MTTL1 3243AG and two pairs of primers
and one set of probes for MTTK 8344AG. The pairs that
gave the best results for each locus are shown in Table 1.
Probes were designed so that the sensor probes span
the mutation sites, with the probe for MELAS designed to
be in the antisense orientation and to match the MTTL1
mutant sequence perfectly (Figure 1A), leading to more
stable hybridization to the mutant sequence. In contrast,
the sensor probe for the MERRF 8344AG mutation was
designed to be in the sense orientation and to match the
normal sequence perfectly (Figure 1B). The gaps be-
tween anchor and sensor probes were four nucleotides
for MELAS and one for MERRF.
PCR conditions (primer, probe, and magnesium con-
centrations and annealing temperatures) and the melting
curve analysis programs were optimized to distinguish
known mutant samples from known normal ones. Asym-
metric PCR was used to produce excessive complemen-
tary strand target for probe hybridization (ie, fivefold more
forward than reverse primer for MELAS and fivefold more
reverse than forward primer for MERRF). Except for
primer concentrations, the reaction conditions and ther-
mocycler programs were identical for both assays, which
were performed using a first generation LightCycler
(Roche Diagnostics). The 10-l reaction contained 2 l of
template DNA, 2 mmol/L MgCl2, 0.3 mol/L each of sen-
sor and anchor probes, 1 l of FastStart DNA Master
Hybridization Probes (Roche Diagnostics), and primers
at 0.6 mol/L (forward) and 0.1 mol/L (reverse) target-
ing MTTL1 or at 0.1 mol/L (forward) and 0.6 mol/L
(reverse) targeting MTTK. Amplification conditions con-
sisted of an initial denaturation step at 95°C for 10 min-
utes, followed by 40 cycles at 95°C for 0 seconds, an-
nealing at 57°C for 10 seconds, and extension at 72°C for
20 seconds, with 20°C/second transition time. Samples
were genotyped by melting curve analysis. Briefly, this
analysis was performed 1) by denaturation at 95°C for 30
seconds, 2) by hybridization to favor binding of probes to
both mutant and normal targets at 58°C for 60 seconds
and 49°C for 60 seconds, respectively (transition rate of
Table 1. Primers and Probes





Mutation position is underlined. Donor probes (anchor probe in MELAS; sensor probe in MERRF) are labeled with fluorescein at the 3 end;
acceptor probes (sensor probe in MELAS; anchor probe in MERRF) are labeled with LC Red640 at the 5 end and phosphorylated on the 3 end to
prevent extension during PCR. F, forward primer; R, reverse primer; S, sensor probe; A, anchor probe.
Figure 1. Mutation detection by real-time PCR and melting curve analysis
using hybridization probes targeting normal or mutant DNA. A: Sequence of
the MELAS MTTL1 region. B: Sequence of the MERRF MTTK region. The sites
of the mutations are indicated in bold, and the sequences corresponding to
the probes are underlined. Note that the sensor probe for MTTL1 is in the
antisense orientation and is complementary to the mutant sequence, whereas
the sensor probe for MTTK is in the sense orientation and is complementary
to the normal sequence.
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20°C/second), and finally 3) by dissociation of reporter
probe from template by slowly raising the temperature to
75°C (transition rate of 0.4°C/second) with stepwise ac-
quisition of fluorescence. The data were converted to
melting peaks by plotting the negative derivative of the
fluorescence with respect to temperature (dF/dT)
against temperature by the LightCycler Data Analysis
Software. The entire amplification and melting curve pro-
gram takes about 45 minutes.
Because of heteroplasmy, ie, the existence of both
normal and mutant mitochondrial DNA, the mutant
mtDNA in patient tissues is usually seen in the presence
of normal mtDNA.10,11 Mutant samples from patients are,
therefore, expected to have two peaks, the amplitudes of
which depend on the degree of heteroplasmy in the
tissue sampled.
Results
Thirteen known positive samples (10 for the MELAS
MTTL1 3243AG mutation and 3 for the MERRF MTTK
8344AG mutation) and 30 samples negative for both
mutations were analyzed by the LightCycler assays. Rep-
resentative melting curves are shown in Figure 2, A and
C. Melting profiles from affected individuals showed two
peaks: for MTTL1, the melting temperatures were 60°C
(mutant) and 51°C (normal); and for MTTK, they were
61°C (normal) and 55°C (mutant). An additional DNA
sample from a cell line (NA11906) that has the 8344AG
mutation was analyzed by the real-time PCR assay, and
the expected result was obtained (Figure 2C). All results
were concordant between the real-time PCR and the
conventional PCR and RFLP methods (Table 2).
To evaluate the effect of varying ratios of mutant to
normal mtDNA, we made dilutions of mtDNA from pa-
tients with known mutations in 10% increments into an
mtDNA sample from a normal individual. The exact mu-
tant/normal mtDNA ratio in these mixtures was unknown
because the extent of heteroplasmy in the patient sam-
ples was not determined by another method. Although
the mutation detection assays were not designed to be
quantitative, the dilution study results show that the
primer and probe sets used for both MERRF MTTK and
MELAS MTTL1 analysis can resolve differences of 10% in
the levels of mutant mtDNA in a normal background
(Figure 2, B and D). Mutations in patient samples could
be detected at levels as low as 10% for either 3243AG
or 8344AG in a mixture with a normal sample.
Figure 2. Melting curves for MELAS MTTL1 3243AG normal (n  1) and mutant (n  3) samples (A) and a dilution series with MELAS MTTL1 3243AG and
normal DNA (B). Melting temperatures are 60°C for mutant DNA and 51°C for normal. Melting curves for MERRF MTTK 8344AG normal (n  1) and mutant
(n  3) samples (C) and a dilution series with MERRF MTTK 8344AG and normal DNA (D). Melting temperatures are 55°C for mutant DNA and 61°C for normal.
The percentages in B and D indicate the relative amounts of a mutant patient sample mixed in with a normal DNA sample.
Table 2. Results of MELAS and MERRF Mutations Detected






Conventional PCR Positive Negative Positive Negative
Positive 10 0 3 0
Negative 0 30 0 30
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Discussion
MELAS and MERRF are rare mitochondrial diseases, and
the heterogeneous clinical manifestations sometimes
make the clinical diagnosis difficult. Detection of disease-
causing mutations will help to confirm the diagnoses.
Conventional PCR-RFLP followed by gel electrophoresis
is the method most commonly used for detecting these
mtDNA mutations. The conventional PCR method is ef-
fective but is relatively labor intensive, and results are
sometimes difficult to interpret because of the presence
of faint bands on the gel. We have developed novel
assays for the common MELAS and MERRF mutations
using real-time PCR followed by melting curve analysis
on the LightCycler. Compared with conventional PCR
methods, the LightCycler method is more rapid and rel-
atively easy to interpret. The LightCycler offers a contin-
uous, closed system to amplify and detect mutation with
minimal risk of cross contamination.
For the MELAS 3243 AG mutation, the sensor probe
was designed to match the mutant sequence perfectly,
leading to more stable hybridization to the mutant se-
quence. As expected, the mutant exhibited a higher Tm
than the wild-type sample (60 versus 51°C, respectively).
In contrast, the sensor probe for the MERRF 8344AG
mutation was designed to perfectly match the normal
sequence; accordingly, the wild-type sample exhibited a
higher Tm than the mutant sample (61 versus 55°C).
All known-positive patient samples (10 for the MELAS
MTTL1 3243AG mutation and 3 for the MERRF MTTK
8344AG mutation) and 30 samples negative for both
mutations analyzed by the LightCycler assays yielded
concordant results between the real-time PCR and the
conventional PCR-RFLP methods. Thus, the new assays
appear to perform as well as conventional methods. The
heights of melting-curve peaks above the baseline of
0.00 units of fluorescence were measured for mutant and
normal DNA, and the fraction of mutant DNA in each
sample was estimated as heightmutant/(heightmutant 
heightnormal). The reproducibility of these ratios was de-
termined in six replicates of a sample from a known
MELAS patient and five replicates of a known MERRF
patient. The mean ratios and coefficients of variation
(CVs) were 0.66 (CV  10.6%) and 0.52 (CV  3.8%),
respectively, which shows that the results are highly
reproducible.
Because of heteroplasmy, quantitation of the relative
amounts of normal and mutant mtDNA would be desir-
able. Several quantitative real-time PCR methods have
been reported, including the use of Molecular Beacons,
TaqMan probes, or SYBR Green technologies.11–13 Our
method was not designed to be quantitative because
there are scant data to suggest that melting peak size is
accurate for quantitative measurement,3 but our assay
has adequate sensitivity to differentiate 10% increments
of patient DNA diluted into normal human DNA samples
and to detect as little as 10% mutant mtDNA in both
MELAS and MERRF patient samples (Figure 2, B and D).
The sensitivity of the assay is actually greater than 10%,
given that the patient samples used for the dilution series
had significant fractions of normal mitochondrial DNA.
Estimates based on relative peak heights are that the
starting samples contained 52% (MERRF) and 66%
(MELAS) mutant molecules; these estimates lead to the
conclusion that the tests are sensitive to 5 to 7% hetero-
plasmy or less. The clinical significance of variations in
the fraction of mutant mtDNA in blood is not clear, given
that mutation load varies by tissue type and that clinical
symptoms are expected to track most closely with certain
tissue types, such as skeletal muscle.10,14 We do not
include estimates of the percentage of heteroplasmy in
clinical reports. There are other, relatively labor-intensive
methods that can be used to quantitate the extent of
heteroplasmy.15–17
In summary, compared with conventional PCR and
RFLP analysis, real-time PCR assays are less time and
labor intensive, relatively easy to interpret, and offer very
low risk of cross contamination. The method that we have
described will be especially useful for laboratories that
are already equipped with a LightCycler. These novel
real-time PCR assays provide a rapid and reliable tech-
nique for molecular confirmation of clinical and biochem-
ical finding in MELAS and MERRF patients.
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